{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:28:00Z","timestamp":1793284080812,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41584-025-01329-3","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:14:37Z","timestamp":1764242077000},"page":"132-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-033X","authenticated-orcid":false,"given":"Fabian","family":"Proft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-8924","authenticated-orcid":false,"given":"Andre L.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-0275","authenticated-orcid":false,"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1084","authenticated-orcid":false,"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-1715","authenticated-orcid":false,"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8492-6342","authenticated-orcid":false,"given":"Ying Ying","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-5328","authenticated-orcid":false,"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-8226","authenticated-orcid":false,"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-6015","authenticated-orcid":false,"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"1329_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin, C. T., Colbert, R. A. & Gladman, D. D. Psoriatic arthritis. N. Engl. J. Med. 376, 957\u2013970 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1329_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald, O. et al. Psoriatic arthritis. Nat. Rev. Dis. Prim. 7, 59 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1329_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108397","volume":"214","author":"LM Perez-Chada","year":"2020","unstructured":"Perez-Chada, L. M. & Merola, J. F. Comorbidities associated with psoriatic arthritis: review and update. Clin. Immunol. 214, 108397 (2020).","journal-title":"Clin. Immunol."},{"key":"1329_CR4","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3899\/jrheum.121500","volume":"40","author":"JA Husted","year":"2013","unstructured":"Husted, J. A., Thavaneswaran, A., Chandran, V. & Gladman, D. D. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J. Rheumatol. 40, 1349\u20131356 (2013).","journal-title":"J. Rheumatol."},{"key":"1329_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","volume":"41","author":"S Gupta","year":"2021","unstructured":"Gupta, S., Syrimi, Z., Hughes, D. M. & Zhao, S. S. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol. Int. 41, 275\u2013284 (2021).","journal-title":"Rheumatol. Int."},{"key":"1329_CR6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.clinthera.2023.05.010","volume":"45","author":"G Ayan","year":"2023","unstructured":"Ayan, G., Ribeiro, A., Macit, B. & Proft, F. Pharmacologic treatment strategies in psoriatic arthritis. Clin. Ther. 45, 826\u2013840 (2023).","journal-title":"Clin. Ther."},{"key":"1329_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates, L. C. et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat. Rev. Rheumatol. 18, 465\u2013479 (2022). These most recent GRAPPA recommendations underpin the domain-based, individualized treatment approach that informed the structure of the C2M\/TR-PsA definitions.","journal-title":"Nat. Rev. Rheumatol."},{"key":"1329_CR8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann. Rheum. Dis. 83, 706\u2013719 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1329_CR9","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/rheumatology\/keaa030","volume":"59","author":"B Hag\u00e8ge","year":"2020","unstructured":"Hag\u00e8ge, B. et al. Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis. Rheumatology 59, 1818\u20131825 (2020).","journal-title":"Rheumatology"},{"key":"1329_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy, G. et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann. Rheum. Dis. 80, 31\u201335 (2021). The EULAR definition of difficult-to-treat RA provided a conceptual and methodological benchmark for structuring the TR-PsA definition.","journal-title":"Ann. Rheum. Dis."},{"key":"1329_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152275","volume":"63","author":"C Philippoteaux","year":"2023","unstructured":"Philippoteaux, C. et al. Characteristics of difficult-to-treat psoriatic arthritis: a comparative analysis. Semin. Arthritis Rheum. 63, 152275 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1329_CR12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40744-022-00461-w","volume":"9","author":"FM Perrotta","year":"2022","unstructured":"Perrotta, F. M., Scriffignano, S., Ciccia, F. & Lubrano, E. Clinical characteristics of potential \u201cDifficult-to-treat\u201d patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol. Ther. 9, 1193\u20131201 (2022).","journal-title":"Rheumatol. Ther."},{"key":"1329_CR13","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/rheumatology\/keae263","volume":"63","author":"KD Vassilakis","year":"2024","unstructured":"Vassilakis, K. D. et al. Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry. Rheumatology 63, 2427\u20132432 (2024).","journal-title":"Rheumatology"},{"key":"1329_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","volume":"18","author":"G Schett","year":"2022","unstructured":"Schett, G. et al. Psoriatic arthritis from a mechanistic perspective. Nat. Rev. Rheumatol. 18, 311\u2013325 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1329_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41584-024-01083-y","volume":"20","author":"S Siebert","year":"2024","unstructured":"Siebert, S. & Marzo-Ortega, H. Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadow. Nat. Rev. Rheumatol. 20, 135\u2013136 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1329_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/ard-2023-224916","volume":"83","author":"KL Winthrop","year":"2024","unstructured":"Winthrop, K. L. et al. Unmet need in rheumatology: reports from the advances in targeted therapies meeting, 2023. Ann. Rheum. Dis. 83, 409\u2013416 (2024). This expert summary highlighted unmet needs in PsA management and emphasized the importance of treatment-resistant phenotypes.","journal-title":"Ann. Rheum. Dis."},{"key":"1329_CR17","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1093\/rheumatology\/keac676","volume":"62","author":"L Hailey","year":"2023","unstructured":"Hailey, L. et al. The top 10 research priorities in psoriatic arthritis: a James Lind Alliance priority setting partnership. Rheumatology 62, 2716\u20132723 (2023).","journal-title":"Rheumatology"},{"issue":"Suppl 2","key":"1329_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3899\/jrheum.2024-0266","volume":"51","author":"G Ayan","year":"2024","unstructured":"Ayan, G. et al. GRAPPA 2023: major projects, key advances, and milestones. J. Rheumatol. 51 (Suppl 2), 65\u201369 (2024).","journal-title":"J. Rheumatol."},{"key":"1329_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003809","volume":"10","author":"S Singla","year":"2024","unstructured":"Singla, S., Ribeiro, A., Torgutalp, M., Mease, P. J. & Proft, F. Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD Open. 10, e003809 (2024). This scoping review mapped the heterogeneous terminology and conceptual gaps around D2T PsA, providing a foundational rationale for this consensus initiative.","journal-title":"RMD Open."},{"key":"1329_CR20","doi-asserted-by":"publisher","first-page":"rkae074","DOI":"10.1093\/rap\/rkae074","volume":"8","author":"AL Ribeiro","year":"2024","unstructured":"Ribeiro, A. L. et al. Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals. Rheumatol. Adv. Pract. 8, rkae074 (2024). This GRAPPA HCP survey identified real-world challenges in PsA treatment and informed the operational separation of C2M-PsA and TR-PsA.","journal-title":"Rheumatol. Adv. Pract."},{"key":"1329_CR21","doi-asserted-by":"publisher","first-page":"keaf207","DOI":"10.1093\/rheumatology\/keaf207","volume":"64","author":"AL Ribeiro","year":"2025","unstructured":"Ribeiro, A. L. et al. Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): insights from an international survey of patients with psoriatic arthritis. Rheumatology 64, keaf207 (2025). This large international, multi-lingual patient survey highlighted the psychosocial, contextual and cultural factors contributing to treatment complexity in PsA.","journal-title":"Rheumatology"},{"key":"1329_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ard.2025.05.188","volume":"84","author":"F Proft","year":"2025","unstructured":"Proft, F. et al. Op0175 establishing definitions for difficult-to-treat psoriatic arthritis (D2T-PSA) and complex-to-manage psoriatic arthritis (C2M-PSA): insights from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiative. Ann. Rheum. Dis. 84, 143\u2013145 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1329_CR23","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ard.2025.01.035","volume":"84","author":"D Poddubnyy","year":"2025","unstructured":"Poddubnyy, D. et al. The Assessment of Spondyloarthritis International Society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis. Ann. Rheum. Dis. 84, 538\u2013546 (2025). This ASAS definition of D2M- and TR-axial SpA guided the development of C2M-PsA and TR-PsA definitions with respect to inflammation-based criteria and stakeholder consensus.","journal-title":"Ann. Rheum. Dis."},{"key":"1329_CR24","doi-asserted-by":"publisher","first-page":"105770","DOI":"10.1016\/j.jbspin.2024.105770","volume":"91","author":"AL Ribeiro","year":"2024","unstructured":"Ribeiro, A. L. & Proft, F. Navigating the complexities of difficult-to-treat axial spondyloarthritis. Jt Bone Spine 91, 105770 (2024).","journal-title":"Jt Bone Spine"},{"key":"1329_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s42358-024-00414-7","volume":"64","author":"A Lucas Ribeiro","year":"2024","unstructured":"Lucas Ribeiro, A. et al. Development of a questionnaire to assess the patient perspective regarding challenges in psoriatic arthritis treatment-a mixed-methods study. Adv. Rheumatol. 64, 72 (2024).","journal-title":"Adv. Rheumatol."},{"key":"1329_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.rdc.2019.07.002","volume":"45","author":"AD Zhang","year":"2019","unstructured":"Zhang, A. D. & Kavanaugh, A. Treat to target in psoriatic arthritis. Rheum. Dis. Clin. North. Am. 45, 505\u2013517 (2019).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"1329_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3899\/jrheum.2023-0530","volume":"50","author":"YY Leung","year":"2023","unstructured":"Leung, Y. Y. et al. Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT working group. J. Rheumatol. 50, 53\u201357 (2023).","journal-title":"J. Rheumatol."},{"key":"1329_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","volume":"76","author":"AM Orbai","year":"2017","unstructured":"Orbai, A. M. et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann. Rheum. Dis. 76, 673\u2013680 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1329_CR29","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s10067-023-06605-9","volume":"42","author":"A Kumthekar","year":"2023","unstructured":"Kumthekar, A., Ashrafi, M. & Deodhar, A. Difficult to treat psoriatic arthritis \u2014 how should we manage? Clin. Rheumatol. 42, 2251\u20132265 (2023).","journal-title":"Clin. Rheumatol."},{"key":"1329_CR30","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40744-023-00574-w","volume":"10","author":"E Lubrano","year":"2023","unstructured":"Lubrano, E., Scriffignano, S. & Perrotta, F. M. Difficult to treat and refractory to treatment in psoriatic arthritis. Rheumatol. Ther. 10, 1119\u20131125 (2023).","journal-title":"Rheumatol. Ther."},{"key":"1329_CR31","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/rheumatology\/keab384","volume":"61","author":"SK Felbo","year":"2022","unstructured":"Felbo, S. K. et al. Do tender joints in active psoriatic arthritis reflect inflammation assessed by ultrasound and magnetic resonance imaging? Rheumatology 61, 723\u2013733 (2022).","journal-title":"Rheumatology"},{"key":"1329_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002011","volume":"8","author":"P Diaz","year":"2022","unstructured":"Diaz, P., Feld, J., Eshed, I. & Eder, L. Characterising axial psoriatic arthritis: correlation between whole spine MRI abnormalities and clinical, laboratory and radiographic findings. RMD Open. 8, e002011 (2022).","journal-title":"RMD Open."},{"key":"1329_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3899\/jrheum.180195","volume":"46","author":"M Elmamoun","year":"2019","unstructured":"Elmamoun, M. et al. Using acute-phase reactants to inform the development of instruments for the updated psoriatic arthritis core outcome measurement set. J. Rheumatol. 46, 266\u2013273 (2019).","journal-title":"J. Rheumatol."},{"key":"1329_CR34","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s10067-020-05065-9","volume":"39","author":"M Haroon","year":"2020","unstructured":"Haroon, M., Gallaghar, P., Ahmad, M. & FitzGerald, O. Elevated CRP even at the first visit to a rheumatologist is associated with long-term poor outcomes in patients with psoriatic arthritis. Clin. Rheumatol. 39, 2951\u20132961 (2020).","journal-title":"Clin. Rheumatol."},{"key":"1329_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11926-024-01146-9","volume":"26","author":"AL Ribeiro","year":"2024","unstructured":"Ribeiro, A. L. & Eder, L. From psoriasis to psoriatic arthritis: ultrasound insights connecting psoriasis with subclinical musculoskeletal inflammation and the path to psoriatic arthritis. Curr. Rheumatol. Rep. 26, 235\u2013247 (2024).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1329_CR36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/1756-185X.14301","volume":"25","author":"A Moshrif","year":"2023","unstructured":"Moshrif, A., Abdel Noor, R., Aly, H., Mortada, M. & Hafez, A. Aging and entheses: an ultrasonographic probing of degenerative enthesopathy in a cohort of 147 healthy subjects. Int. J. Rheum. Dis. 25, 481\u2013488 (2023).","journal-title":"Int. J. Rheum. Dis."},{"key":"1329_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.reuma.2020.12.005","volume":"18","author":"P Falsetti","year":"2022","unstructured":"Falsetti, P. et al. Diffuse peripheral enthesitis in metabolic syndrome: a retrospective clinical and power doppler ultrasound study. Reumatol. Clin. 18, 273\u2013278 (2022).","journal-title":"Reumatol. Clin."},{"key":"1329_CR38","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.clinthera.2023.05.009","volume":"45","author":"LH Hailey","year":"2023","unstructured":"Hailey, L. H. et al. Lifestyle modifications and nonpharmacologic interventions to improve outcomes in psoriatic arthritis: a systematic review. Clin. Ther. 45, 841\u2013851 (2023).","journal-title":"Clin. Ther."},{"key":"1329_CR39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40744-025-00759-5","volume":"12","author":"E Lubrano","year":"2025","unstructured":"Lubrano, E., Ambrosino, P. & Perrotta, F. M. Psychological health in the management of patients with psoriatic arthritis: an intricate relationship. Rheumatol. Ther. 12, 407\u2013419 (2025).","journal-title":"Rheumatol. Ther."},{"key":"1329_CR40","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/acr.25358","volume":"76","author":"P Mease","year":"2024","unstructured":"Mease, P., Reed, G., Ogdie, A., Pappas, D. A. & Kremer, J. M. Prevalence of fibromyalgia and widespread pain in psoriatic arthritis: association with disease severity assessment in a large US registry. Arthritis Care Res. 76, 1313\u20131321 (2024).","journal-title":"Arthritis Care Res."},{"key":"1329_CR41","first-page":"1871","volume":"43","author":"D Currado","year":"2025","unstructured":"Currado, D. et al. From pain catastrophising to multidimensional psychological distress: unravelling the complexity of difficult-to-treat psoriatic arthritis. Clin. Exp. Rheumatol. 43, 1871\u20131878 (2025).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1329_CR42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40744-022-00443-y","volume":"9","author":"LC Coates","year":"2022","unstructured":"Coates, L. C. et al. Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real-world evidence. Rheumatol. Ther. 9, 803\u2013821 (2022).","journal-title":"Rheumatol. Ther."},{"key":"1329_CR43","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3899\/jrheum.190677","volume":"47","author":"M Zardin-Moraes","year":"2020","unstructured":"Zardin-Moraes, M. et al. Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis. J. Rheumatol. 47, 839\u2013846 (2020).","journal-title":"J. Rheumatol."},{"key":"1329_CR44","doi-asserted-by":"publisher","first-page":"103638","DOI":"10.1016\/j.autrev.2024.103638","volume":"23","author":"F Proft","year":"2024","unstructured":"Proft, F. et al. Treatment strategies for spondyloarthritis: implementation of precision medicine \u2014 or \u201cone size fits all\u201d concept? Autoimmun. Rev. 23, 103638 (2024).","journal-title":"Autoimmun. Rev."},{"key":"1329_CR45","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.jaad.2023.06.058","volume":"89","author":"JQ Jin","year":"2023","unstructured":"Jin, J. Q. et al. Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: a 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry. J. Am. Acad. Dermatol. 89, 974\u2013983 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1329_CR46","doi-asserted-by":"publisher","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","volume":"5","author":"L Eder","year":"2025","unstructured":"Eder, L. et al. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis. Lancet Rheumatol. 5, e716\u2013e727 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1329_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41584-025-01229-6","volume":"21","author":"A Zabotti","year":"2025","unstructured":"Zabotti, A., Aydin, S. Z., David, P., Di Matteo, A. & McGonagle, D. Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis. Nat. Rev. Rheumatol. 21, 237\u2013248 (2025). This Perspective article highlights the clinical relevance of separating inflammatory from non-inflammatory mechanisms in PsA management and research.","journal-title":"Nat. Rev. Rheumatol."},{"key":"1329_CR48","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/art.42780","volume":"76","author":"F Fagni","year":"2024","unstructured":"Fagni, F., Motta, F., Schett, G. & Selmi, C. Difficult-to-treat psoriatic arthritis: a conceptual approach. Arthritis Rheumatol. 76, 670\u2013674 (2024). This conceptual framework reinforced the importance of distinguishing therapeutic refractoriness from broader contextual disease complexity in PsA.","journal-title":"Arthritis Rheumatol."},{"key":"1329_CR49","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.clinthera.2023.04.005","volume":"45","author":"AL Ribeiro","year":"2023","unstructured":"Ribeiro, A. L. et al. Challenges in the management of psoriatic arthritis in Latin America: a systematic review. Clin. Ther. 45, 860\u2013867 (2023).","journal-title":"Clin. Ther."},{"key":"1329_CR50","first-page":"159","volume":"41","author":"CG Gialouri","year":"2023","unstructured":"Gialouri, C. G. et al. Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients\u2019 perception? Clin. Exp. Rheumatol. 41, 159\u2013165 (2023).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1329_CR51","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00296-021-04925-0","volume":"42","author":"H Kancharla","year":"2022","unstructured":"Kancharla, H. et al. Fibromyalgia influences health-related quality of life and disease activity in psoriatic arthritis. Rheumatol. Int. 42, 511\u2013517 (2022).","journal-title":"Rheumatol. Int."},{"key":"1329_CR52","doi-asserted-by":"publisher","first-page":"102602","DOI":"10.1016\/j.coi.2025.102602","volume":"95","author":"D Chakraborty","year":"2025","unstructured":"Chakraborty, D. & Raychaudhuri, S. P. Concept of dual immune inhibitors for the treatment of drug-resistant psoriatic disease. Curr. Opin. Immunol. 95, 102602 (2025).","journal-title":"Curr. Opin. Immunol."},{"key":"1329_CR53","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/art.41765","volume":"73","author":"JU Scher","year":"2021","unstructured":"Scher, J. U., Ogdie, A., Merola, J. F. & Ritchlin, C. Moving the goalpost toward remission: the case for combination immunomodulatory therapies in psoriatic arthritis. Arthritis Rheumatol. 73, 1574\u20131578 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1329_CR54","first-page":"563","volume":"51","author":"DG Fern\u00e1ndez-\u00c1vila","year":"2024","unstructured":"Fern\u00e1ndez-\u00c1vila, D. G. et al. Pan American league of associations for rheumatology recommendations for the treatment of psoriatic arthritis. J. Rheumatol. 51, 563\u2013576 (2024).","journal-title":"J. Rheumatol."},{"key":"1329_CR55","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell, P. S. et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann. Rheum. Dis. 72, 986\u2013991 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1329_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001170","volume":"6","author":"E Lubrano","year":"2020","unstructured":"Lubrano, E. et al. Assessment of the patient acceptable symptom state (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open. 6, e001170 (2020).","journal-title":"RMD Open."},{"key":"1329_CR57","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3899\/jrheum.171411","volume":"46","author":"P Macchioni","year":"2019","unstructured":"Macchioni, P. et al. Ultrasonographic and clinical assessment of peripheral enthesitis in patients with psoriatic arthritis, psoriasis, and fibromyalgia syndrome: the ULISSE study. J. Rheumatol. 46, 904\u2013911 (2019).","journal-title":"J. Rheumatol."},{"key":"1329_CR58","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1093\/rheumatology\/keaf258","volume":"64","author":"K Meridor","year":"2025","unstructured":"Meridor, K. et al. Association of clinical and sonographic factors with discrepancy between patients\u2019 and evaluators\u2019 global assessments in psoriatic arthritis. Rheumatology 64, 5058\u20135064 (2025).","journal-title":"Rheumatology"},{"key":"1329_CR59","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2014-206971","volume":"74","author":"P Mandl","year":"2015","unstructured":"Mandl, P. et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann. Rheum. Dis. 74, 1327\u20131339 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1329_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen, J. S. et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann. Rheum. Dis. 77, 3\u201317 (2018).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01329-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01329-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01329-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T01:02:35Z","timestamp":1769648555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01329-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1038\/s41584-025-01329-3","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"7 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.P. has received grants and personal fees from Novartis, Eli Lilly and UCB and personal fees from AbbVie, AMGEN, BMS, Celgene, Janssen, Hexal, Medscape, Moonlake, MSD, Pfizer and Roche outside the presented work. A.L.R. has received honoraria and support for attending conferences from Novartis, Eli Lilly, UCB, AbbVie and Janssen, all outside the presented work. S.S. has received consulting fees from AbbVie, Johnson & Johnson and UCB, speaker fees from Johnson & Johnson, and research grants from AbbVie, Eli Lilly and Prometheus Biosciences. V.C. has received grants from AbbVie, Amgen and Eli Lilly and honoraria for advisory board member roles from AbbVie, BMS, Eli Lilly, Fresenius Kabi, Janssen, Novartis and UCB; V.C.\u2019s spouse is an employee of AstraZeneca; and V.C. is supported by the Dr. Dafna D. Gladman Chair in Psoriatic Arthritis Research, a joint Hospital-University Named Chair between the University of Toronto, the University Health Network, and the UHN Foundation. W.L. has received research funding from Amgen, Janssen, Leo and Regeneron. C.L. has acted as a consultant for Tonix Pharmaceuticals, and owns stock with Amgen and Arcutis. E.R.S. has participated in advisory boards for, given conferences for and\/or received grants from AbbVie, Amgen, Bristol-Myers Squibb, Elea, Glaxo, Janssen, Lilly, Montpellier, Novartis, Pfizer, Raffo, Roche, Sandoz and UCB. T.B. has received research funding from Amgen, Castle, CorEvitas, Novartis, Pfizer and Regeneron; she has served as an adviser for AbbVie, Arcutis, Aslan, Boehringer-Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, Leo, Lilly, Pfizer, Novartis, Sanofi, Sun, Takeda and UCB; and she is a speaker for AbbVie, Amgen, Arcutis, BMS, Dermavant, Galderma, Janssen, Lilly, Leo, Ortho, Sanofi and UCB. A.D. has participated in consulting and advisory boards for Bristol Myers Squibb, Eli Lilly, J&J, Novartis, Pfizer, UCB, and has received research grants from Bristol Myers Squibb, Eli Lilly, J&J, MoonLake, Novartis, Pfizer and UCB. K.d.V. has participated in consulting and advisory boards for Bristol Myers Squibb, Eli Lilly, J&J, Novartis, Pfizer, UCB, AlfaSigma, Moonlake & Allegro, and has received research grants from Pfizer and UCB. L.E. has received grants from AbbVie, UCB, Novartis, J&J, Eli Lilly, Pfizer, Novo Nordisk, Fresenius Kabi and Amgen, and has participated in consulting for BMS, AbbVie, UCB, Novartis, J&J and Eli Lilly. M.K. has received speakers bureau fees from AbbVie, Amgen, Asahi-Kasei Pharma, Ayumi Pharma, BMS, Chugai, Daiichi Sankyo, Eisai, Janssen, Lilly, Novartis, Tanabe-Mitsubishi and UCB, and has acted as a consultant for AbbVie, Amgen, Asahi-Kasei Pharma, Ayumi Pharma, BMS, Chugai, Gilead, Janssen, Lilly, Novartis, Takeda, Tanabe-Mitsubishi and UCB. Y.Y.L. has received speaking fees from AbbVie, DKSH, Jassen, Novartis and Pfizer, outside of the present work. E.L. has received speaker\u00b4s fees from AbbVie, Lilly, Janssen, Novartis and UCB. D.M. has received grants and speaker fees from AbbVie, BMS, Novartis, Eli Lilly, UCB, Celgene, Janssen, Moonlake and Pfizer. D.P. has received research grants from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB, consulting fees from AbbVie, Eli Lilly, Greywolf Therapeutics, Janssen, Merk, Moonlake, Novartis, Pfizer and UCB, and speaker fees from AbbVie, Canon, Eli Lilly, Janssen, Medscape, Novartis, Peervoice, Pfizer and UCB; he serves as a member of the executive committee of ASAS, a member of the steering committee of GRAPPA, and editor of\n                      Therapeutic Advances in Musculoskeletal Disease\n                      . L.S. has received honoraria from AbbVie, Almirall, Novartis, Janssen, Lilly, UCB, Pfizer, Bristol-Myers-Squibb, Boehringer Ingelheim, Amgen, Medac, Moonlake, Leo Pharma, Takeda, Galderma, Biogen, Celgene, Celltrion, Sanofi and Fresenius Kabi for consulting and speaker roles, and has received support for travel from AbbVie, Janssen, Lilly, Novartis, UCB, Bristol-Myers-Squibb, Boehringer Ingelheim and Leo Pharma. F.V.d.B. has received consulting fees from AbbVie, Alfasigma, Celltrion, Eli Lilly, Fresenius Kabi, GreyWolf Therapeutics, Janssen, Novartis, UCB and Xencor. P.M. has received research grants, consulting fees and speaker fees from AbbVie, Acelyrin, Amgen, Bristol Meyers Squibb, Century, Eli Lilly, Inmagene, Johnson & Johnson, Moonlake, Novartis, Pfizer, Takeda and UCB, and is a data safety board member of Genascence.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}